166.50
+0.30%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lotus Pharmaceutical Co
Its shares trade on Taiwan Stock Exchange under the ticker 1795.TW. It has been listed since 13 December 2004. In the fiscal year to 31 December 2025, it reported revenue of TWD 20.51bn and net income of TWD 4.72bn. At that date it held total assets of TWD 106.15bn and shareholders' equity of TWD 23.78bn.
Lotus Pharmaceutical Co., Ltd. engages in the manufacture, distribution, research and development of pharmaceutical products. The company is headquartered in Taipei City, Taipei. The company went IPO on 2004-12-13. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The firm is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The firm mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Dec 2004
- Website
- lotuspharm.com.tw ↗
Leadership
Pay as last reported
- Mr. Robert WessmanChairman of the Board, since 2015
- Ms. Eeling ChanChief Financial Officer, Deputy General Manager-Finance & Accounting
- Mr. Vamsi KosarajuChief Operating Officer
- Ms. Gwen HsiehChief Information Officer
- Mr. Petar VazharovGeneral Manager, Director, since 2016
- Mr. Bjartur ShenDeputy General Manager - Strategy and Finance
- Mr. Edin BuljubasicDeputy General Manager-Legal and Compliance
- Mr. Manish ChawlaDeputy General Manager-Research & Development
- Mr. Prashant GodseDeputy General Manager - Business Development
- Ms. Mohan LiaoCorporate Governance Officer
- Mr. Nat AtivitavasDirector
- Mr. Arni HardarsonDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lotus Pharmaceutical Co Ltd has a strong presence in the pharmaceutical industry, with a well-established reputation for producing high-quality drugs.
- The company boasts a diverse product portfolio, encompassing a wide range of therapeutic areas, which helps to mitigate the risk associated with dependence on a single product or market.
- Lotus Pharmaceutical Co Ltd is known for its strong research and development capabilities, enabling it to constantly innovate and introduce new drugs to the market.
Weaknesses
- One of the weaknesses of Lotus Pharmaceutical Co Ltd is its relatively small market share compared to some of its larger competitors.
- The company heavily relies on government policies and regulations, which could pose a risk if there are changes in the political environment or healthcare policies.
- There might be limitations in the company's manufacturing capabilities, which could impact its ability to scale up production to meet increased demand.
Opportunities
- The increasing demand for generic drugs presents a significant growth opportunity for Lotus Pharmaceutical Co Ltd, as it specializes in the production of affordable generics.
- Expansion into new geographic markets and partnerships with international pharmaceutical companies can help the company tap into new customer bases and gain access to advanced technologies.
- Lotus Pharmaceutical Co Ltd could explore diversification into related healthcare sectors such as medical devices or healthcare services to broaden its revenue streams.
Threats
- Intense competition within the pharmaceutical industry poses a threat to Lotus Pharmaceutical Co Ltd, as other companies strive to capture market share and drive down prices.
- The potential for stricter regulatory requirements and more complex approval processes can increase costs and delay product launches.
- Economic downturns and fluctuations in currency exchange rates can impact the affordability and purchasing power of customers, affecting the company's sales and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.